Status:
COMPLETED
Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Growth Disorders
Eligibility:
All Genders
3-14 years
Brief Summary
The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormo...
Detailed Description
This study will compare Fibroblast Growth Factor 23 levels in children with and without growth hormone deficiency. Children with growth hormone deficiency will have levels taken before starting growth...
Eligibility Criteria
Inclusion
- Twenty children with significant short stature \< 3rd percentile, ages 3-14 years, and referred to Children's Hospital of Alabama
- Normal healthy volunteer children 3-18 years with normal stature
Exclusion
- Patients on medication including GH
- Patients with concomitant hormonal abnormalities
- Patients with disorders of calcium and phosphate metabolism
- Active neoplasms
- Closed epiphysis
- Known bone disorders
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00334945
Start Date
April 1 2006
End Date
August 1 2011
Last Update
November 16 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.